Jiao Qu1, Xin Shu2, Wenjing Zhang1, Mengyuan Xu1, Ying Wang1, Lituan Wang2, Lei Zhang2, and Su Lui1
1Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital of Sichuan University, Chengdu, China, 2College of Computer Science, Sichuan University, Chengdu, China
Synopsis
Brain metastases
detection and segmentation on
magnetic resonance images is laborious, error-prone and often irreproducible for
radiologists and radiation oncologist. We present a specific deep slice-crossed
network with local weighted loss to automatically detect and segment brain metastases
on contrast-enhanced T1WI images. The results demonstrated the good
performance, high robustness and generalizability of the model. In addition,
compared with radiologists, the model showed higher sensitivity and increased
efficiency in identifying and segmenting brain metastases. The results jointly suggested that the proposed model
is a promising tool to assist the workflow in the clinical practice.
Purpose
To detect and
segment brain metastases (BM) on contrast-enhanced three-dimensional T1-weighted
images (T1WI), we develop and evaluate a model based on deep slice-crossed
network with local weighted loss.Method
In this
multicenter study, contrast-enhanced 3D-T1WI images from 1482 patients with
15235 brain metastases were included. First, a dataset of 1000 patients with
11686 brain metastases from West China Hospital headquarter was used to conduct
preliminary training and validation of the deep slice-crossed network model.
Performance of the model was evaluated using recall, Dice Similarity
Coefficient (DSC) and false-positives per patient (FP). Afterward, to test
generalizability, robustness, detection efficiency and segmentation performance
of the model, another five independent heterogeneous datasets were used,
including 1) external data:100 BM cases from Wen jiang Branch of West China
Hospital, 2) 108 BM patients with different primary tumors(36 cases with lung
cancer, 36 cases with breast cancer, 36 cases with digestive tract cancer), 3) 120
data originated from different manufacturers or different strength fields(40
cases from GE 3.0 T, 40 cases from Philips 3.0 T, 40 cases from Siemens 3.0 T and 40 cases
from Siemens 1.5 T, respectively), 4) 50 patients with single tiny BM, 5)
isolated BM with different sizes (34 cases with a diameter of 10 mm and 30
cases with a diameter of 20 mm on the cross section, respectively). Result
Overall, our model
produced a recall of 0.88, a DSC of 0.90 and a FP per patient of 1.0,
respectively. In the external test set, the network yielded a recall of 0.82,
which was slightly lower than that of the internal validation set (Z =
-2.92, p = 0.003). There was no significant difference in DSC between
the internal and the external dataset (0.90 vs. 0.88, Z = -1.06 and p
= 0.29). For data from different primary tumors, the model achieved a
recall of 0.86 with a DSC of 0.85 in the lung cancer group, a recall of 0.84
with a DSC of 0.83 in the breast cancer group and a recall of 0.91 with a Dice
rate of 0.90 in the digestive tract cancer group, and there were no significant
differences in recall and DSC among these three groups (H = 2.04 and
0.24, p = 0.36 and 0.89, respectively). For data obtained from different
manufacturers but with the same filed strengths, the network demonstrated a
recall of 0.89 and a DSC of 0.90 in Siemens 3.0 T group, a recall of 0.73 and a DSC
of 0.82 in GE 3.0 T group, and a recall of 0.83 and a DSC of 0.85 in Philips 3.0 T group (H
= 9.60 and 7.25, p = 0.01 and 0.03, respectively). After Bonferroni
correction, only the recall of Siemens 3.0 T group and GE 3.0 T group (H = -2.97, p
= 0.01), and the DSC of the Philips 3.0 T group and Siemens 3.0 T group were
significantly different (H = -2.64, p = 0.03). For data obtained
from the same manufacturer but with different field strengths, the model
achieved a recall of 0.89 with a DSC of 0.90 in Siemens 3.0T group and a recall
of 0.84 with a DSC of 0.89 in Siemens 1.5T group, no significant difference
being found between the 2 groups (Z = 1.77 and 0.23; p = 0.08 and
0.82, respectively). In the diagnostic accuracy comparison trial, the model
exhibited a sensitivity of 72.0% and a FP per patient of 0.94, which were both
higher than those of the resident radiologists and the attending radiologists
(a sensitivity of 48.5% and 68.1% with the FP per patient of 0.13 and 0.32,
respectively). For single tiny BM, reading time of the model was significantly
shorter than that of radiologists (2.29 ± 0.45 sec/case vs. 21.53 ± 0.64
sec/case, Z = -6.15, p < 0.01). For isolated BM with different
diameters, the average time for the model to segment each lesion were 2.27 ±
0.35 s for 10mm group and 2.30 ± 0.59 s for 20mm group, both of which were
shorter than that of radiologists (Z = -5.09 and -4.78, all p <0.001).Discussion and Conclusion
The
present study established a specific deep learning model to
automatically detect and segment brain metastases on contrast-enhanced T1WI
images. The results not only demonstrated the
model’s good performance, but also verified the model’s high robustness and
generalizability. In addition, comparison tests with radiologists showed the
model’s higher sensitivity and efficiency, as expected. Afore-mentioned
results suggested that the proposed model is a promising tool to assist the
workflow in the clinical scenario.Acknowledgements
This work was
supported by the National Natural Science Foundation of China (Grant Nos.
8212018014, 82071908, and 82101998), Sichuan Science and Technology Program
(Grant Nos. 2021JDTD0002 and 2020YJ0018), the Science and Technology Project of
the Health Planning Committee of Sichuan (Grant No. 20PJ010), 1.3.5 Project for
Disciplines of Excellence, West China Hospital, Sichuan University (Project No.
ZYYC08001 and ZYJC18020). SL also acknowledges the support from Humboldt
Foundation Friedrich Wihelm Bessel Research Award and Chang Jiang Scholars
(Program No. T2019069).References
1. Suh JH, Kotecha R, Chao
ST, et
al. Current
approaches to the management of brain metastases. Nat Rev Clin Oncol,
2020;17(5):279-299.
2. Owonikoko TK, Arbiser J,
Zelnak A, et al. Current approaches to the treatment of metastatic brain
tumours. Nat Rev Clin Oncol, 2014;11(4):203-222.
3. Kaal EC, Niël CG, Vecht
CJ. Therapeutic management of brain metastasis. Lancet Neurol,
2005;4(5):289-298.
4. Carden CP, Agarwal R,
Saran F, et al. Eligibility of patients with brain metastases for phase I
trials: time for a rethink? Lancet Oncol, 2008;9(10): 1012-1017.
5. Olson JJ, Kalkanis SN,
Ryken TC. Congress of neurological surgeons systematic review and
evidence-based guidelines for the treatment of adults with metastatic brain
tumors: Executive summary. Neurosurgery, 2019; 84(3): 550-552.
6. Zhou Z, Sanders JW,
Johnson JM, et al. Computer-aided Detection of Brain Metastases in T1-weighted
MRI for Stereotactic Radiosurgery Using Deep Learning Single-Shot Detectors.
Radiology, 2020;295(2):407-415.
7. Noguchi T, Uchiyama F, Kawata Y, et al. A Fundamental
Study Assessing the Diagnostic Performance of Deep Learning for a Brain
Metastasis Detection Task. Magn Reson Med Sci, 2020;19(3):184-194.
8. Bousabarah K, Ruge M, Brand JS, et al. Deep
convolutional neural networks for automated segmentation of brain metastases
trained on clinical data. Radiat Oncol, 2020;15(1):87.
9. Dikici E, Ryu JL, Demirer M, et al. Automated Brain
Metastases Detection Framework for T1-Weighted Contrast-Enhanced 3D MRI. IEEE J
Biomed Health Inform, 2020;24(10):2883-2893.